In den USA aus Abwärtstrend ausgebrochen, letzter Kurs 70 cents, nachbörslich 81
Paradigm Signs $8.4 Million Addition to $23.8 Million Contract With NIEHS $2 Million of
RESEARCH TRIANGLE PARK, N.C., Apr 24, 2003 /PRNewswire-FirstCall via
Paradigm Genetics, Inc. (Nasdaq: PDGM) today announced that the
Institute of Environmental Health Sciences (NIEHS) has exercised an
its existing five-year $23.8 million contract (Contract NO1-ES-25497) with
Paradigm, providing for an additional $8.4 million for toxicogenomics
studies.
Two million dollars of this modification is currently allotted and earmarked
Paradigm to perform research for the National Toxicology Program (NTP).
generated from this toxicogenomics research will be included in the NTP's
program to better understand the effects of short and long-term
exposures to
chemicals. The data will become part of the Chemical Effects in Biological
Systems (CEBS) database, a publicly accessible relational database that
will
contain information on the biological effects of chemicals and other
agents and
their mechanism of action.
"Part of the NTP's mission is to strengthen the science base in toxicology
and
provide information about potentially toxic chemicals to health regulatory
and
research agencies, the scientific and medical communities, and the
public," said
Kenneth Olden, Ph.D., Director, NIEHS and NTP. "Working with Paradigm
Genetics,
we seek the best possible biological information to fulfill our mission."
"We are proud and honored that the NTP recognizes our expertise in DNA
microarray analysis and chose to work with us for its toxicogenomics
research,"
said Heiri Gugger, Ph.D., President and CEO of Paradigm Genetics. "This
additional $8.4 million modification is a great confirmation of our
momentum in
the field of toxicogenomics and our growing presence in human health."
The NTP is an interagency program consisting of relevant toxicology
activities
among the National Institutes of Health's National Institute of
Environmental
Health Sciences, the Centers for Disease Control and Prevention's
National
Institute for Occupational Safety and Health, and the Food and Drug
Administration's National Center for Toxicological Research.
About Paradigm Genetics
Paradigm is a biotechnology company aiming to increase R&D productivity
by
focusing its integrated suite of technologies on the product development
cycle,
from target discovery to subsequent enhancement of the safety and
efficacy
profiles of development candidates in agriculture and human health.
Paradigm
chooses a systems biology approach to understand gene function in the
context of
biological pathways, to develop assays and biomarkers for molecular
diagnostic
solutions tailored to the needs of our partners. Paradigm's proprietary
Gene to
Cell to System(TM) approach has three major components: gene
expression
profiling, biochemical profiling (also known as metabolomics) and data
integration and coherence. For more information, visit
www.paradigmgenetics.com. This press release contains forward-looking statements, including
statements
regarding the use and impact of data generated from the toxicogenomics
research.
Such forward-looking statements are based on management's current
expectations
and are subject to a number of risks, factors and uncertainties that may
cause
actual results, events and performance to differ materially from those
referred
to in the forward-looking statements. These risks, factors and
uncertainties
include, but are not limited to, Paradigm's early stage of development,
history
of net losses, technological and product development uncertainties,
reliance on
research collaborations, uncertainty of additional funding and ability to
protect its patents and proprietary rights. Certain of these and other risks
are
identified in Paradigm's Form 10-K for the year ended December 31, 2002,
filed
with the Securities and Exchange Commission. The Company does not
intend to
update any of the forward-looking statements after the date of this
release to
conform these statements to actual results or to changes in our
expectations,
except as may be required by law.
SOURCE Paradigm Genetics, Inc.
CONTACT: Melissa Matson, Director, Corporate Communications of
Paradigm Genetics, Inc., +1-919-425-3000, or media,
Prateek Patnaik,
or investors, Amy Garay, of Noonan Russo Presence Euro
RSCG, +1-212-845-4200,
for Paradigm Genetics, Inc.
URL:
www.paradigmgenetics.com www.prnewswire.com Copyright (C) 2003 PR Newswire. All rights reserved.
Das ist aber längst nicht alles:
- Paradigm WKN
936980 hält Cash ca. in Höhe von über 1,2$ pro Aktie
- Paradigm WKN
936980 forscht auch im Bereich SARS und das birgt eine Menge
Fantasie!!!
- Am 1.5. sollen neben deutlich besser als erwarteten Zahlen auch NEWS zu
Forschungsergebnissen kommen!!!
Fazit: Die 1€.-Marke dürfte im Vorfeld des 1.5. erreicht werden, der Wert ist deutlich
im Aufwärtstrend!!!
Siehe auch Chart:
Widerstand bei 60-65 cents genommen!
Bis 80 cents kaufen und mitverdienen - es geht gerade richtg los!
PARADIGM GENETICS WKN
936980 Hört sich auch alles sehr gut an:
Apr 23 2003
TRADE NEWS: Agilent Technologies Offers
Industry's First 60-mer Oligonucleotide Rat
Microarray for Genome Screening, Toxicogenomic
Research Microarrays Incorporate Unique, Proven
Toxic Response Genes from the NIEHS to Assist
Scientists in the Discove
Apr 23 2003
You Are Cordially Invited to the Paradigm Genetics
First Quarter 2003 Financial Results Conference Call
Webcast
Apr 15 2003
Paradigm Strengthens Human Health Unit Through
Key Appointments In Medical Informatics and
Computational Biology Industry Expert Michael
Liebman Appointed to Scientific Advisory Board And
Brian Bullard Hired as Senior Director of
Computational System
Brokerstar
Der alte Börsenfuchs Star Ikone hatte wie so oft das richtige Näschen! ;)
